Cart
sales@molnova.com
MC-Val-Cit-PAB
CAS No. 159857-80-4
MC-Val-Cit-PAB( —— )
Catalog No. M19787 CAS No. 159857-80-4
MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 41 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMC-Val-Cit-PAB
-
NoteResearch use only, not for human use.
-
Brief DescriptionMC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.
-
DescriptionMC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number159857-80-4
-
Formula Weight572.65
-
Molecular FormulaC28H40N6O7
-
Purity>98% (HPLC)
-
SolubilityDMSO:≥ 22 mg/mL (38.42 mM)
-
SMILESCC(C)[C@H](NC(=O)CCCCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(CO)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
molnova catalog
related products
-
Roniacol
3-Pyridinemethanol is a useful synthetic intermediate.
-
13-Diaminopropane
13-Diaminopropane is a common synthesis reagent used in the synthesis of cholinesterase inhibitors and thrombosis inhibitors.
-
Ladanein
Ladanein is a phytochemicals inhibitor that is known to disrupt the interactions of core and other hepatitis C virus (HCV) proteins.Ladanein possesses free radicals DPPH and ABTS +.scavenging activity, it also displays moderate (20-40 microM) activities against K562, K562R (imatinib-resistant), and 697 human leukemia cell lines.
